WealthShield Partners LLC Has $251,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

WealthShield Partners LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,372 shares of the medical equipment provider’s stock after selling 585 shares during the quarter. WealthShield Partners LLC’s holdings in Zimmer Biomet were worth $251,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ZBH. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet during the 4th quarter valued at $473,000. Geode Capital Management LLC boosted its position in shares of Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after buying an additional 125,852 shares during the period. M&T Bank Corp grew its holdings in shares of Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock valued at $2,884,000 after buying an additional 8,709 shares in the last quarter. KLCM Advisors Inc. acquired a new position in Zimmer Biomet during the fourth quarter valued at $7,825,000. Finally, Peddock Capital Advisors LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth about $654,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.1 %

NYSE:ZBH opened at $106.00 on Tuesday. The company’s 50 day moving average is $105.85 and its 200-day moving average is $107.44. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The firm has a market cap of $21.10 billion, a price-to-earnings ratio of 23.82, a P/E/G ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the firm posted $2.20 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.91%. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ZBH shares. Royal Bank of Canada lowered their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays cut their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Truist Financial reiterated a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.